

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Find an MSK Doctor or Cancer Specialist](#)  
[Make an Appointment](#)  
[Back](#)

[Refer a Patient](#)  
[Refer a Patient](#)  
[Refer a Patient](#)

## ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

Pediatric Oncology

Neuroblastoma and Developmental Tumors of Childhood

Immunotherapy

[View all](#) 



[Dr. Cheung's Office Information](#) 



Languages: English

## About Me

## What I Do at MSK

- Enid A. Haupt Chair of Pediatric Oncology

## Get To Know Me

I am a pediatric oncologist at MSK Kids who specializes in immunologic approaches to diagnose and treat pediatric cancers. My main focus is the treatment of neuroblastoma, a tumor arising from primitive cells of the sympathetic nervous system which primarily affects young children.

[Read more](#)

+

## My Role at MSK

A pediatric hematologist-oncologist is a doctor who treats cancers of the blood in children and adolescents. This doctor is a hematologist (HEE-muh-TAH-loh-jist) who diagnoses and treats blood disorders. They also are an oncologist (cancer doctor).

## Areas of Expertise

### My Specialties

Pediatric Oncology

Neuroblastoma and Developmental Tumors of Childhood

Immunotherapy

Autologous Bone Marrow Transplantation

## Education & Honors

### Education

MD, Harvard Medical School

PhD, Harvard Medical School

## Residencies

Pediatrics - Stanford University

## Fellowships

Pediatric Hematology/Oncology - Stanford University

## Board Certifications

Pediatrics

Pediatric Hematology-Oncology

## Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage.](#)

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](tel:646-497-9176).

## Contact and Location

Dr. Cheung sees patients at one location.


#### Office Phone

 [646-888-2313](tel:646-888-2313)

#### Location

 New York, NY

#### [Memorial Sloan Kettering Cancer Center](#)

 1275 York Avenue  
New York, NY 10065

[Get Directions](#)

---

Looking to see a doctor at a different location? [See all MSK locations.](#)

## Colleagues


Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

[See all Pediatrics doctors](#) →

## Clinical Trials

Clinical Trials Investigated by Dr. Cheung

[Molecular Characterization of Neuroblastic Tumors and Clinical Outcome](#)



### Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials](#) →

## Research and Publications

[View Dr. Cheung's Lab](#)

[Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NV, Larson SM, Dunkel IJ. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018 Jun 15. pii: S1470-2045\(18\)30322-X. doi: 10.1016/S1470-2045\(18\)30322-X.](#)

[Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung NK. Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma – A Phase 1 Clinical Trial. JAMA Oncol. 2018 September 20. doi:10.1001/jamaoncol.2018.4005](#)

[Hoseini SS, Guo HF, Wu ZH, Hatano MN, Cheung NKV. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Advances 2\(11\):1250-1258, 2018](#)

[Wu ZH, Guo HF, Xu H, Cheung NKV. Development of a tetravalent anti-GPA33/anti-CD3 bispecific antibody for colorectal cancers. Mol Cancer Ther. 2018 Aug 6. pii: molcanther.0026.2018. doi: 10.1158/1535-7163.MCT-18-0026.](#)

Read more

+

## Publications on PubMed

Visit PubMed for a full listing of Dr. Cheung's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

[See all on PubMed](#) →

## Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Nai-Kong V. Cheung discloses the following relationships and financial interests:

Abpro Inc

Equity; Intellectual Property Rights

Biotec Pharmacon

Intellectual Property Rights

Eureka Therapeutics Inc

Equity

Y-mAbs Therapeutics, Inc.

Equity; Intellectual Property Rights

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#). For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org).

[View all disclosures](#) →

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center